

From: [Janice Castillo](#)  
To: [Gildner, Jean](#)  
Subject: RE: BLA125586 Portola Label  
Date: Wednesday, May 02, 2018 9:37:53 AM  
Attachments: [image013.png](#)  
[image019.png](#)

---

Jean,

I accept the milestone dates given below. A formal submission to the BLA will be made this morning.  
Janice

---

From: Gildner, Jean [mailto:Jean.Gildner@fda.hhs.gov]  
Sent: Tuesday, May 01, 2018 5:15 PM  
To: Janice Castillo  
Subject: RE: BLA125586 Portola Label

Dear Janice,

Please see the following comments from the Clinical reviewer:

The final protocol submission date of April 17, 2018 is based on the submission to the IND (and therefore not the BLA). So if the plan is to submit the final protocol submission date of April 17, 2018 under SN0135 of the BLA that is fine. Please include the dates for the rest of the milestones so the revised milestones should read as:

- **Final protocol submission date: April 17, 2018**
- First patient enrolled: January 31, 2019
- Completion Date of Patient Accrual: September 30, 2022
- Study Completion Date: October 31, 2022
- Date of Final Study Report Submission: April 30, 2023

Please acknowledge receipt of this email.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP)

**Regulatory Project Manager**  
**Center for Biologics Evaluation and Research**  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8296  
[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Janice Castillo [mailto:jcastillo@Portola.com]  
**Sent:** Tuesday, May 01, 2018 7:24 PM  
**To:** Gildner, Jean <Jean.Gildner@fda.hhs.gov>  
**Subject:** RE: BLA125586 Portola Label

Hi Jean,  
Receipt acknowledged.

Also, can you please respond to my email question on the RCT milestone date.

Janice

---

From: Gildner, Jean [mailto:Jean.Gildner@fda.hhs.gov]  
Sent: Tuesday, May 01, 2018 3:16 PM  
To: Janice Castillo  
Subject: BLA125586 Portola Label

Dear Janice,

Please see attached the final label. There are 3 comments for you. Please revise and send back via email and as an amendment as soon as possible.  
Please confirm receipt of this email.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP)  
**Regulatory Project Manager**  
**Center for Biologics Evaluation and Research**  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**  
Tel: 240-402-8296

[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.